roles of residues f206 and v367 in human cytochrome p450...
TRANSCRIPT
DMD # 71662
1
Roles of Residues F206 and V367 in Human Cytochrome P450 2B6: Effects of
Mutations on Androgen Hydroxylation, Mechanism-based Inactivation and Reversible
Inhibition
Hsia-lien Lin, Haoming Zhang, Cesar Kenaan, and Paul F. Hollenberg Department of Pharmacology, University of Michigan, Ann Arbor, Michigan 48109
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
2
Running title: Roles of F206 and V367 in the Catalytic Activity of CYP2B6
*To whom correspondence should be addressed: Paul F. Hollenberg, Department of
Pharmacology, 2220C MSRB III, 1150 West Medical Center Drive, Ann Arbor, MI
48109-5632.
Phone: (734) 764-647-3121. Fax: (734) 763-5378.
E-mail: [email protected]
Number of text pages: 41
Number of Tables: 3
Number of Figures: 9
Number of References: 37
Number of words in the Abstract: 250
Number of words In the Introduction: 797
Number of words in the Discussion: 1408
Abbreviations: Andro, androstenedione; BG, bergamottin; BPA, 4-tert-
butylphenylacetylene; CYP2B1, rat cytochrome P450 2B1; CYP2B4, rabbit cytochrome
P450 2B4; CYP2B6, human cytochrome P450 2B6; EFC, 7-ethoxy-4-
(trifluoromethyl)coumarin; ESI, electrospray ionization; F206A, Phe206 to Ala mutation
of 2B6; GSH, glutathione; HFC, 7-hydroxy-4-(trifluoromethyl)coumarin; HPLC, high
pressure liquid chromatography; LC-MS, liquid chromatography-mass spectrometry; LC-
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
3
MS/MS, liquid chromatography-tandem mass spectrometry; reductase, NADPH-
cytochrome P450 reductase; SRS, substrate recognition site; Testo, testosterone; TFA,
trifluoroacetic acid; T302V, Thr302 to Val mutation of 2B6; V367A, V367 to Ala
mutation of 2B6; WT, wild type 2B6.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
4
Abstract
The crystal structures of human P450 2B6 (CYP2B6) indicate that Phe206 and Val367
are in close proximity to the substrate binding site and suggest that both residues may
play important roles in substrate metabolism and inhibitor binding. To test this
hypothesis, we investigated the effects of mutating these residues to Ala on the
regiospecificity of CYP2B6 for the metabolism of testosterone (Testo) and
androstenedione (Andro). For Testo metabolism, 16β-OH-Testo formation by F206A
was <5% of wild type (WT), whereas the V367A mutant exhibited a doubling of 16α-
OH-Testo formation with a 50% decrease in 16β-OH-Testo formation compared to WT.
Significant alterations in the regiospecificity for Andro metabolism were also observed.
To investigate the roles of these two residues in the metabolic activation of mechanism-
based inactivators, tert-butylphenylacetylene (BPA) and bergamottin (BG) were used to
test the susceptibility to inactivation. Although the rates of inactivation of both mutants
by BG were not significantly decreased compared to WT, the efficiency of inactivation
by BPA of both mutants was more than an order of magnitude lower. Our results
demonstrate that Phe206 plays a crucial role in determining the specificity of 2B6 for the
16β-hydroxylation of Testo and Andro and that it also plays an important role in BG
binding and mechanism-based inactivation by BPA. In addition, Val367 dramatically
enhances the catalytic activity of CYP2B6 toward Andro and plays an important role in
mechanism-based inactivation by BPA. The results presented here show the important
roles of Phe206 and Val367 in interactions of CYP2B6 with substrates and
inactivators/inhibitors and are consistent with the crystal structures.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
5
Introduction
The CYP2B enzymes are an outstanding model system for investigating structure-
function relationships of the P450s (Gotoh 1992; Zhao and Halpert, 2007). The 16β-
hydroxylations of testosterone (Testo) and androstenedione (Andro), are specific markers
for rat CYP2B1 activity (Waxman et al., 1983; Wood et al., 1983). From 1990 to 2000,
our understanding of the functional and structural importance of residues in the P450 2B
subfamily was based primarily on studies of the rat isoform. Site-directed mutagenesis
studies of CYP2B1 have shown that Phe115, Phe206, Leu209, Ser294, Ala298, Thr302,
and Gly478 are required for the 16β-hydroxylation of Testo and Andro (Kedzie et al.,
1991; He et al., 1994; Szklarz et al., 1995). A combination of approaches involving
mechanism-based inactivators and site-directed mutagenesis further identified Ile114,
Thr302, Leu363, Val367 and Gly478 as functionally important active site residues
(Kedzie et al., 1991; He et al., 1994, 1995; Kent et al., 1997). All of these residues are
located in the putative substrate recognition sites (SRSs) for the P450 2B subfamily as
proposed by Gotoh (1992). Prior to the determination of the first X-ray crystal structure
of a mammalian P450, the combined approaches of site-directed mutagenesis,
mechanism-based inactivators, and molecular modeling based on structures of bacterial
P450s proved to be invaluable for gaining insights into the structural and functional
relationships of CYP2B1 (Domanski and Halpert, 2001; Kent et al., 2001). A significant
breakthrough occurred when the first X-ray crystal structure of rabbit CYP2C5 was
solved in 2000 (Williams et al., 2000). Using the CYP2C5 crystal structure as a template,
a CYP2B6 homology model was constructed and used for analysis of the structure-
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
6
activity relationships of human CYP2B6 (Wang and Halpert, 2002; Spatzengger et al.,
2003).
Because of its potential pharmacological/clinical significance, interest in CYP2B6
has increased significantly over the years (Turpeinen et al., 2006). CYP2B6 appears to be
the only functional member of the human 2B family and the average relative contribution
of CYP2B6 to the total hepatic CYP content is reported to range from 2% to 10% (Wang
and Tompkins, 2008). CYP2B6 is one of the most polymorphic CYP genes in humans
and it metabolizes a number of clinically relevant drugs (Zanger et al., 2007). However,
direct extrapolation of animal data based on CYP2B1 to human CYP2B6 has limitations
(Wang and Tompkins, 2008). For example, CYP2B6 metabolizes Testo and 7-ethoxy-4-
(trifluoromethyl)coumarin (EFC) at a much slower rate than CYP2B1, but readily
hydroxylates RP 73401 (3-cyclopentyloxy-N-(3,5-dichlor-4-methoxybenzamide), which
is not a substrate of CYP2B1 (Stevens et al., 1997; Domanski et al., 1999). So far, the
SRS residues believed to be involved in the structure-function relationship of CYP2B6
have not been investigated in detail.
Recently, the crystal structures of CYP2B6 complexed with 4-(4-
chlorophenyl)imidazole, 4-benzylpyridine, and 4-(4-nitrobenzyl)pyridine were solved
and revealed that Phe206 and Val367 are in the active site of CYP2B6 within 4 Å of the
bound inhibitors (Gay et al., 2010; Shah et al., 2011). Comparisons of the three crystal
structures showed that rearrangements of Phe206 and Phe297 were required to
accommodate the various ligands within the active site (Shah et al., 2011). Moreover,
crystal structures of the open and closed forms of CYP2B4 adducted with tert-
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
7
butylphenylacetylene (BPA) were solved and revealed that Phe206 points into, while
Phe297 points out of the active site to avoid clashing with the tert-butyl and phenyl
groups of BPA (Gay et al., 2011). Docking of BPA into the CYP2B6 crystal structure
showed that Val367 is in close proximity to both the heme iron and the acetylene triple
bond of BPA (Lin et al., 2011). Our previous studies on Thr205, which is more than 6Å
away from the heme in CYP2B1, have demonstrated the importance of Thr205 in
determining the substrate specificity and product formation as well as influencing the
susceptibility of CYP2B1 to mechanism-based inactivation (Lin et al., 2003 and 2004).
Taken together, these observations suggest that Phe206 and Val367 may play a critical
role in substrate binding. Both Phe206 and Val367 are conserved in the active sites of
CYP2B1, CYP2B4 and CYP2B6. BPA and bergamottin (BG) have previously been
characterized as potent mechanism-based inactivators of CYP2B6. It was of great interest
to compare the effect of substituting Phe206 and Val367 of CYP2B6 on androgen
metabolism and mechanism-based inactivation by two structurally unrelated compounds
BPA and BG.
Our studies show that the product profiles for the metabolism of Testo and Andro
metabolism were dramatically altered by substitution of either of the two amino acid
residues in CYP2B6. These substitutions also altered the efficiency of inactivation by
BPA and the reversible inhibition of the enzyme by BG. These results are discussed in
the context of the functional and structural roles of Phe206 and Val367 in CYP2B6 and
clearly demonstrate that inferences from crystal structures of CYP2B6 have functional
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
8
bearing with respect to product distribution and susceptibility to inhibition and
inactivation .
Materials and Methods
Chemicals. NADPH, GSH, catalase, and BPA were purchased from Sigma-Aldrich (St.
Louis, MO). BG was from Indofine Chemical Co., Inc. (Hillsborough, NJ). Testo, Andro,
16α-OH-Testo, 16β-OH-Testo, 16α-OH-Andro, and 16β-OH-Andro were all purchased
from Steraloids Inc. (Newport, RI). EFC was from Invitrogen Corp. (Carlsbad, CA). 7-
Hydroxy-4-(trifluoromethyl)coumarin (HFC) was obtained from Oakwood Products, Inc.
(West Columbia, SC). All other chemicals and solvents were of the highest purity
available from commercial sources.
Site-directed Mutagenesis. The human wild type CYP2B6 (WT) plasmid was used as a
template to construct two mutants at positions Phe206 and Val367. The mutations were
carried out using an in vitro QuickChange site-directed mutagenesis kit (Stratagene
product, Invitrogen, Santa Clara, CA). The primer 5’-CTTGTTCTACCAGACT
GCTTCACTCATCAGCTC-3’ was used for the Phe206 to Ala conversion (F206A
mutant). The primer 5’-CTCCCCATGGGTGCGCCCCACATTGTC-3’ was used for the
Val367 to Ala conversion (V367A mutant). The nucleotides that were substituted to yield
the altered amino acid residues are underlined and in bold. The mutations were confirmed
by DNA sequencing carried out at the University of Michigan Biomedical Core Facility
(Ann Arbor, MI).
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
9
Assay for the Mechanism-Based Inactivation of the P450s. WT CYP2B6, the two
CYP2B6 mutants and NADPH-cytochrome P450 reductase (reductase) were expressed in
Escherichia coli and purified according to previously published procedures (Lin et al.,
2005). The purified P450s and reductase were reconstituted at 22ºC for 30 min as
previously described (Lin et al., 2003). The primary reaction mixtures contained 500
pmol P450, 1000 pmol reductase, 2 mM GSH, 100 units of catalase, and BPA or BG in a
total volume of 250μl in 100 mM potassium phosphate buffer (pH 7.7). After incubation
of the primary reaction mixture with 1 mM NADPH at 22ºC with various concentrations
of BPA (1 μM to 300 μM) or BG (1 μM to 20 μM), 3μl aliquots were removed at
different time points (0 to 6 min) and added to 300 μl of a secondary reaction mixture
containing 50 μM EFC and 200 μM NADPH for 10 min. The reactions were terminated
by adding 125 μl of acetonotrile and the formation of the HFC product was determined
using a fluorescence plate reader (excitation 410 nm; emission, 510 nm) on a Wallace
Victor II 1420-042 multilabel counter (PerkinElmer, Shelton, CT). The calculations to
obtain the kinetic values describing the mechanism-based inactivation were performed as
previously described (Lin et al., 2005; Zhang et al., 2009).
Metabolism of Testo and Andro. Aliquots (250 pmol) of the WT and F206A and
V367A mutants of 2B6 in the reconstituted system were prepared as described above and
were incubated with 0.2 mM Testo and 0.5 mM NADPH in 100 mM potassium
phosphate buffer (pH 7.7) at 37°C for 15 min. 6β-OH-Testo (internal standard) was
added to the reaction mixture and the metabolites were extracted with ethyl acetate, dried
down under nitrogen gas and analyzed by high pressure liquid chromatography (HPLC)
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
10
as previously described (Lin et al., 2003). The dried products were dissolved in 65%
methanol and resolved using a Microsorb-MV C18 reverse-phase column (5 μm, 4.6 x
250 mm; Varian, Walnut Creek, CA). Testo and its metabolites were separated under
isocratic conditions with 65% methanol at a flow rate of 0.7 ml/min. The eluates
containing 16α-OH-Testo, 16β-OH-Testo, and Andro were monitored at 254 nm. For
Andro metabolism, aliquots (125 pmol) of the WT, F206A mutant and V367A mutant in
the reconstituted systems were prepared as described above for Testo except that the
internal standard was 16β-OH-Testo. The major metabolites are 16α-OH-Andro and 16β-
OH-Andro.
Metabolism of BG. Aliquots (500 pmol) of the WT, F206A and V367A 2B6 in the
reconstituted system were prepared as described above and incubated with 50 μM BG
and 1 mM NADPH in 100 mM potassium phosphate buffer (pH 7.7) at 37°C for 15 min.
5-Methoxypsoralen (internal standard) was added to the reaction mixture and the
metabolites were extracted with ethyl acetate for HPLC analysis and monitored at 310
nm according to our previous method (Lin et al., 2005; Kent et al., 2006).
Reversible Inhibition of the P450s. For the reversible inhibition studies, WT and F206A
were reconstituted with reductase as described above. Different concentrations of EFC (1
μM to 100 μM) were prepared and incubated with the 2B6 reconstituted systems together
with various concentrations of BG (0 to 4 μM) for 5 min and then the reactions were
initiated by adding 200 μM NADPH to measure the HFC product. The kinetic
parameters, Km and Kcat, were fitted to the Michaelis-Menten equation and the Ki was
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
11
obtained by global fitting to a mixed model inhibition equation using Prism software
(GraphPad software Inc., San Diego, CA).
LC-MS/MS Analysis of GSH Conjugates of BPA. The samples (250 pmol in 250 μl
reaction mixture) of WT 2B6, F206A, and V367A were prepared in a reconstituted
system as described above and incubated with 1 mM NADPH and 100 μM BPA for 30
min. The reactions were terminated by adding 1 ml of acetonitrile. The mixtures were
centrifuged at 13,200 g at room temperature for 10 min. The supernatants were dried
under N2 gas and re-suspended in 100 µl of 50% methanol. The samples were analyzed
on a C18 reverse-phase column (Luna, 3 µm, 4.6 x 100 mm, Phenomenex, Torrance, CA)
with solvent A (0.1% acetic acid/water) and solvent B (0.1% acetic acid/acetonitrile).
Elution with 30% B for 5 min followed by a gradient to 40% B over 15 min and then
increasing linearly to 90% B over 15 min at a flow rate of 0.3 ml/min was used. The
column effluent was directed into the ESI source of a LCQ mass spectrometer (Thermo
Fisher Scientific). The ESI conditions were: sheath gas flow rate, 90 arbitrary units;
auxiliary gas, 30 arbitrary units; spray voltage, 4.5 kV; capillary temperature, 170°C;
capillary voltage, 30 V; and tube lens offset, 25 V. The data were acquired in positive
ion mode using the Xcalibur software (Thermo Fisher Scientific) with one full scan
followed by two data-dependent scans of the most intense and the second most intense
ions.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
12
Results
Location of the Residues and Structures of the Substrates. The locations of Phe206,
Thr302 and Val367 in the CYP2B6 crystal structure (Gay et al., 2010) are displayed in
Fig. 1A. Phe206 is located in the F-helix in the SRS-2 region (199LNLFYQTFSLIS209)
shown in magenta. Thr302 is located in the I-helix in the SRS-4 region
(290LNTLSLFFAGTETFS304) shown in green. Thr302 is included because it is the site of
covalent binding for the reactive intermediate of BPA (Lin et al., 2011). V367 is located
in the β1-4 sheet in the SRS-5 region (360SDLLPMGVPH369) shown in blue. The
chemical structures of the Testo, Andro, EFC, BPA and BG used in this study are shown
in Fig. 1B. The circled areas on the structures of BPA and BG indicate the sites of
metabolism resulting in the formation of reactive intermediates.
Catalytic Activities of the WT and F206A and V367A Mutants of CYP2B6. To
investigate whether or not mutations of residue Phe206 or Val367 affect the protein
function, the EFC deethylation activity was used to determine the specific activity and Km
values of the WT and mutant P450s. The Km values obtained for all three P450s were
very similar (~4 μM). The specific activity of WT was 2.8 nmol/min/nmol P450, whereas
the specific activities of the F206A and V367A mutants were 1.68 and 1.01
nmol/min/nmol P450 for EFC deethylation activities, respectively.
In order to investigate the effect of the mutation of F206 and V367 on the regio-
and stereo-specificity of 2B6, the metabolism of Testo by the WT and mutant proteins
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
13
was investigated. Fig. 2A illustrates representative HPLC chromatographic profiles for
the products generated from the metabolism of Testo catalyzed by the WT, F206A
mutant and V367A mutant. 6β-OH-Testo (eluting at 8.1 min) was used as an internal
standard and three major metabolites: 16α-OH-Testo (8.9 min), 16β-OH-Testo (10.8
min), and Andro (18.4) were produced. In general, the conversion of the 17β-hydroxyl to
the 17-keto group to form Andro was catalyzed to a similar extent by all three P450s. For
F206A, the amount of 16α-OH-Testo produced was similar to that of WT, but the
formation of 16β-OH-Testo was almost completely suppressed as compared to the WT.
In contrast, the V367A mutant exhibited a greater than 2-fold increase in the 16α-
hydroxylase activity and more than a 50% decrease in the 16β-hydroxylase activity as
compared to WT. The unidentified product that eluted at 12.5 min was observed for all
P450s. Although the hydroxylation activity of F206A was low overall, a new metabolite
eluting at ~12 min was observed.
The stereo-selectivity of the enzymes was further studied by using Andro as the
substrate and 16β-OH-Testo (eluting at 10.0 min) as the internal standard. The HPLC
chromatographic metabolite profiles are shown in Fig. 3A. For WT, 16β-OH-Andro
(eluting at 7.6 min) was the predominant product and 16α-OH-Andro (eluting at 8.3 min)
was formed at very low levels. For the F206A mutant, the formation of 16β-OH-Andro
was almost completely suppressed whereas 16α-OH-Andro formation became more
prominent. For the V367A mutant, the generation of both the 16α-OH-Andro and 16β-
OH-Andro was dramatically enhanced as compared to the WT 2B6. To be able to better
visualize the regio- and stereo-selectivity for the metabolism of the two androgens by the
three P450s, 16β-OH-Testo was set as the 100% control for Testo metabolism and 16β-
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
14
OH-Andro was set as the 100% control for Andro metabolism. The means from two
separate experiments are displayed in Fig. 2B for Testo metabolism and in Fig. 3B for
Andro metabolism. The total Testo metabolites formed by F206A and V367A are 30 and
80% of WT, respectively. The total Andro metabolites formed by F206A and V367A are
34 and 320% of WT, respectively.
To visualize the relative stereo-selectivity of the variants, the total activities for
the formation of the 16α-OH and 16β-OH products of Testo or Andro for each P450
were normalized as 100% and the relative amounts of 16α-OH and 16β-OH products
were calculated and displayed in Fig. 4. It is clear that WT selectively metabolizes both
androgens at the 16β-position whereas the F206A mutant selectively metabolizes both
androgens at the 16α-position. In contrast, V367A metabolizes Testo to the 16α-OH and
16β-OH products in almost equal amounts whereas its stereo-selectivity for Andro is
essentially similar to that of the WT.
Mechanism-based inactivation by BPA and BG. In addition to investigating the effects
of the mutation of the two residues on the catalytic activity of CYP2B6 for a single
substrate giving a single product (EFC) and for substrates giving multiple products
(Testso and Andro), we thought it would be important to investigate the effects of these
mutations on mechanism-based inactivation. To investigate whether the mutants were
still capable of being inactivated by BPA and BG, the WT and mutant P450s were
incubated with 10 μM BPA or 10 μM BG for varying lengths of time (0, 3, 6 and 9 min)
in the primary reaction mixture. The Ln % of activity remaining was calculated at each
time point and plotted against incubation time. As seen in Fig. 5, BPA and BG are both
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
15
relatively efficient mechanism-based inactivators of the WT, as expected (Lin et al.,
2005; Lin et al., 2011). BPA inactivated both mutants much more slowly as compared
with WT, but inactivation by BG was not significantly altered by the mutation.
Kinetic Constants for the Mechanism-Based Inactivation. Mechanism-based
inactivation of CYP2B6 by BPA or BG was further characterized by incubating CYP2B6
with various concentrations of BPA or BG for time points varying from 0 to 9 min at
each concentration. For inactivation by BPA, 1 to 10 μM, 10 to 300 μM and 5 to 100 μM
BPA were used for WT, F206A, and V367A, respectively. For inactivation by BG, 1 to
20 μM BG was used for all three P450s. Similar to our previous studies, the present
results showed that the inactivation is time-and concentration-dependent (Lin et al., 2005;
Lin et al., 2011). The kinetic constants were calculated as described under Material and
Methods and are summarized in Table 1. For inactivation by BPA, the mutation of
Phe206 and Val367 to Ala did not significantly alter the kinact, but drastically increased
the KI. As a consequence, the efficiency of inactivation by BPA (as measured by the
kinact/KI) decreased by more than one order of magnitude, suggesting that Phe206 and
Val367 may contribute significantly to the mechanism of BPA-mediated inactivation. In
contrast to what was seen with BPA, the efficiency of the inactivation of both mutants by
BG did not decrease. Interestingly, although no significant change was observed with
V367A, a significant decrease in the KI resulted in a more than 4-fold increase in the
efficiency for inactivation of the F206A variant compared with WT.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
16
Reversible Inhibition of WT and the F206A Mutant by BG. The data presented in Fig.
5 clearly showed that, at time zero, BG inhibits the EFC deethylation activity of F206A
by ~80% of the WT. The observation that mutation of Phe206 to Ala potentiated
inhibition by BG was further investigated. The IC50 values for BG inhibition of WT and
F206A were characterized using 100 μM EFC as the substrate (Fig. 6). The IC50 values
for inhibition by the WT and F206A mutant by BG are 0.4 μM and 0.02 μM,
respectively. Thus, F206A is inhibited 50% by BG at a concentration that is 20-fold
lower as compared to that for the WT. Furthermore, the type of reversible inhibition was
assessed by using varying concentrations of EFC (1 μM to 100 μM EFC) as substrate
with various concentrations of BG as the inhibitor. For WT, the range of BG
concentrations used ranged from 0 to 1 μM. For F206A, the range of BG concentrations
was from 0 to 0.02 μM. The results are presented in Fig. 7A for WT and Fig. 8A for
F206A. The Km and kobs for the P450s are shown in Table 2. As can be seen in Table 2,
the Km increased and the kobs decreased with increasing concentrations of BG for both
P450s. Therefore, we determined the Ki values by nonlinear regression global fitting to
the mixed type inhibition equation. The apparent Ki values for WT and F206A are 0.12
and 0.004 μM respectively. Previously, Paine and coworkers used linear regression
Dixon plots to characterize a mixed type, reversible inhibition of human intestinal
CYP3A4 by BG (Paine et al., 2004). We have analyzed the inhibition of WT and F206A
in a similar manner. Dixon plots for both WT and F206A are also presented in Figs. 7B
and 8B, respectively. The Ki values were estimated to be ~0.2 μM for WT and ~0.005
μM for F206A. In short, the Ki values calculated using both methods are in good
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
17
agreement and thus it is clear that the residue at position 206 has a significant effect (~30
fold) on the inhibitory potency of BG.
Metabolism of BG by WT, F206A and V367A. The metabolism of BG by the three
P450s was determined by HPLC analysis (Fig. 9). As reported previously, WT 2B6
generates two major metabolite peaks, M3 is 5’-OH-BG and M4 is a mixture of 6’-OH-
BG and 7’-OH-BG (Kent et al., 2006). The F206A mutant exhibited very low level
activity for BG metabolism compared to WT2B6, whereas the V367A mutant showed a
significant change in the regio-selectivity for the formation of the primary mono-
hydroxylated products.
Discussion
Although extensive studies have been performed to elucidate the functional
and structural importance of some SRS residues in rat CYP2B, very little is known about
the role of SRS residues in its human CYP2B counterpart (Domanski and Halpert, 2001;
Kent et al., 2001; Zhao and Halpert, 2007; Halpert, 2011; Zhang et al., 2011). The
studies described here were based on an analysis of the crystal structure of CYP2B6 that
suggested that Phe206 and Val367, two highly conserved SRS residues in human
CYP2B6, were in close proximity to the substrate binding site and thus might have
significant effects on substrate metabolism and susceptibility to inhibition/inactivation.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
18
CYP2B1 hydroxylates Testo to form equal amounts of 16β-OH and 16α-OH
(16β:16α = 1), whereas it hydroxylates Andro primarily at the 16β-position (16β:16α =
~8) (Waxman et al., 1983; He 1994; Lin et al., 2003). As shown here, CYP2B6
metabolizes both Testo (16β:16α = 5) and Andro (16β:16α = 17) primarily at the 16β-
position and is the only human P450 capable of hydroxylating Testo at the 16β-position
(Imaoka et al., 1996). Our data also demonstrate the highly stereo-selective
hydroxylation activity of CYP2B6 for the 16β position of both Testo and Andro, that is
much greater than that of CYP2B1. The total 16α-OH and 16β-OH metabolites formed
as well as the 16β-OH:16α-OH ratio for Testo and Andro observed with CYP2B6 were
compared to results published for CYP2B1 and CYP2B4 (Table 3). These data suggest
that when Phe206 was changed to Ala, the 16β-OH activities of CYP2B1 and CYP2B6
were markedly suppressed for both androgens. Substitution of Val367 with Ala resulted
in the following: (1) a decrease in the 16β:16α ratio for Testo with CYP2B6, but an
increase with CYP2B4; and (2) an increase in the 16β:16α ratio of Andro with CYP2B1
and 2B4, but not with CYP2B6. The total activities for Testo and Andro metabolism by
CYP2B6 and its V367A mutant show a similar pattern when compared to CYP2B4 and
its V367A mutant, but are quite different from what was seen with CYP2B1 and its
mutant. WT CYP2B4 exhibited a very low 16β:16α ratio with Testo as compared to
CYP2B1 and CYP2B6. In spite of some structural and catalytic similarities between
these proteins, our results clearly show the limitations of directly extrapolating data
obtained from animal CYPs to human CYPs.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
19
Although the total hydroxylation activities for both androgens by the F206A
mutant are much lower than that for WT (Fig. 2 and Fig. 3), the WT selectively produces
the 16β-OH metabolite, whereas the F206A variant selectively produces the 16α-
ΟΗ metabolite (Fig. 4). This dramatic conversion in stereo-selectivity was not observed
following mutation of Thr205 on the F-helix of CYP2B1 (Lin et al., 2003). Phe206 is
also located in the F-helix, which plays a role in substrate access to the active site. Based
on the results presented here, it appears that during the entrance into and binding of Testo
and Andro to the active site that the presence of Ala at position 206 may lead to a
distortion or twisting of the D-ring of both Testo and Andro that reorients the 16α-face
toward the heme iron. This finding agrees with a previous study using the A82W P450
mutant of BM3 as a tool for the regioselective hydroxylatiom of Testo at the 16β-position
(Rea et al., 2012). It is interesting to note that aromatic residues at this position favor
selectivity for steroid hydroxylation at the 16β-position for both CYP2B6 and P450
BM3. In contrast, the impact of Ala substitution at Val367 on the stereo-selectivity is not
as profound as substitution at Phe206. V367 is very close to the heme and the
replacement by Ala creates a more open active site leading to a 3-fold increase in the
formation of the products of Andro metabolism with no significant effect on the stereo-
selectivity.
When Phe206 or Val367 were replaced by Ala, the efficiency of this
inactivation reaction (kinact/KI), was drastically diminished, which can be primarily
attributed to an increase in the KI. Docking BPA into the active site of CYP2B6 in the
crystal structure and the crystal structure of BPA-adducted CYP2B4 revealed that Phe206
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
20
and Val367 are in close contact with BPA (Gay et al., 2011; Lin et al., 2011). Thr302 has
previously been identified as the site for covalent modification of CYP2B6 by a reactive
intermediate of BPA resulting in mechanism-based inactivation (Lin et al., 2011). The
possible reasons contributing to the decrease in the susceptibility of F206A mutant to
inactivation would include the following: (1) the three dimensional structure of the active
site that facilitates covalent binding of the BPA reactive intermediate to the hydroxyl
moiety of Thr302 is distorted in the mutants and is less effective at steering the
intermediate to the Thr; (2) the reactive intermediate of BPA formed by the mutants
reacts more readily with water molecules in the active site than it reacts with the OH
moiety of Thr302; or (3) the mutations increase the mobility of BPA in the active site of
mutants, thereby facilitating its egress from the active site over its reaction with Thr302.
The substitution of Val367 with Ala creates more space in the active site that may either
increase the mobility of BPA in the active site or may allow BPA to move further away
from the heme iron. Therefore, the orientation of BPA’s triple bond relative to the side
chain of Thr302 in the V367A mutant may be very different from that in the WT. Any
one or a combination of these possibilities may be likely to reduce the interaction of BPA
with the mutant proteins and thus, higher concentrations of BPA would be required for
the inactivation.
Unlike the results observed with BPA, the efficiency for the mechanism-based
inactivation of the two mutants by BG actually improved. The KI for F206A is
approximately 5-fold lower than that for WT, indicating that BG binds with higher
affinity to F206A. This mutation also leads to increased sensitivity to reversible
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
21
inhibition by BG with a Ki value that is ~30-fold lower than WT, indicating the
importance of residue 206 in determining the binding affinity and inhibitor sensitivity.
We investigated to see if the increase in the inhibitory potency observed for F206A was
seen with other furanocoumarin containing compounds and found that both the efficiency
of mechanism-based inactivation and the potency of reversible inhibition for F206A by
the furanocoumarins 5-methoxypsoralen and 8-methoxypsoralen were similar to WT. The
primary difference in the structures of these furanocoumarins is that the BG contains a
geranyl side chain at the methoxy position (+137 Da), whereas both 5-methoxypsoralen
and 8-methoxypsoralen have a methyl group (+15 Da). When BG enters the substrate
access channel, it is possible that the bulky geranyl side chain may impede access to the
active site due to steric hindrance by the phenyl moiety of Phe206 in the F-helix.
Removal of the Phe side chain then may open up the path for BG to enter the active site
for metabolic activation and to better expose the Thr302 for reaction with the activated
intermediate of BG. Thermodynamic measurements of the Phe206 to Ala substitution of
CYP2B4 support rearrangement of the active site observed in the crystal structure of the
1-(4-chlorophenyl)imidazole complex and may help to explain our results for BG
inactivation of the F206A mutant of CYP2B6 (Zhao et al., 2007). We have previously
demonstrated that CYP2B6 readily hydroxylates BG on the geranyl side chain to give the
5’-OH-BG, 6’-OH-BG and 7’-OH-BG (Kent et al., 2006). The very low level of these
hydroxylated metabolites formed by F206A suggests that for BG binding the
furanocoumarin moiety may be reoriented such that it is bound more tightly in the
vicinity of the heme iron than the geranyl side chain when compared to its binding to
WT. Because oxidation of the furan ring to generate a furanoepoxy intermediate is
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
22
responsible for mechanism-based inactivation by BG, the preferential binding of the
furanocoumarin moiety near the heme iron may explain the 5-fold lower KI for
mechanism-based inactivation by BG of F206A when compared to the WT.
In conclusion, these studies demonstrate for the first time that Phe206 and
Val367, the two highly conserved SRS residues in close proximity to the substrate
binding site of CYP2B6, have important functional roles in the interaction of this P450
with substrates, inhibitors, and inactivators. Substitution of Phe206 or Val367 with
another amino acid residue such as alanine can have profound effects on substrate
metabolism, regiospecificity, mechanism-based inactivation, and inhibition.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
23
Acknowledgments
We thank Dr. Richard Neubig, Department of Pharmacology, University of Michigan
(Ann Arbor, MI) for the use of the Wallace Victor II plate reader. We are grateful to Dr.
Ute M. Kent for critical reading of the manuscript.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
24
Authorship Contributions
Participated in research design: Lin, Zhang, Kenaan
Conducted experiments: Lin and Kenaan
Contributed new reagents or analytic tool: Lin, Kenaan, Zhang
Performed data analysis: Lin, Kenaan, Zhang
Wrote or contributed to the writing of manuscript: Lin, Zhang, Hollenberg
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
25
References
Domanski TL, Schultz KM, Roussel F, Stevens JC, and Halpert JR (1999) Structure-
function analysis of human cytochrome P450 2B6 using a novel substrate, site-directed
mutagenesis, and molecular modeling. J Pharmacol Exp Ther 290:1141-1147.
Domanski TL and Halpert JR (2001) Analysis of mammalian cytochrome P450 structure
and function by site-directed mutagenesis. Curr Drug Metab 2:117–137.
Gay SC, Shah MB, Talakad JC, Maekawa K, Roberts AG, Wilderman PR, Sun L, Yang
JY, Huelga SC, Hong WX, Zhang Q, Stout CD, and Halpert JR (2010) Crystal structure
of a cytochrome P450 2B6 genetic variant in complex with inhibitor 4-(4-
chlorophenyl)imidazole at 2.0-Å resolution. Mol Pharmacol 77:529-538.
Gay SC, Zhang H, Wilderman PR, Roberts AG, Liu T, Li S, Lin HL, Zhang Q, Woods
VL, Stout CD, Hollenberg PF, and Halpert JR (2011) Structural analysis of mammalian
cytochrome P450 2B4 covalently bound to the mechanism-based inactivator tert-
butylphenylacetylne: insight into partial enzymatic activity. Biochemistry 50:4903-4911.
Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins
inferred from comparative analyses of amino acid and coding nucleotide sequences. J
Biol Chem 267:83-90.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
26
Halpert JR (2011) Structure and function of cytochromes P4502B: from mechanism-
based inactivators to X-ray crystal structures and back. Drug Metab Dispos 39:1113-
1121.
He Y, Luo Z, Klekotka PA, Burnett VL, and Halpert JR (1994) Structural determinants
of cytochrome P450 2B1 specificity: evidence for five substrate recognition sites.
Biochemistry 33:4419–4424.
He YQ, He YA, and Halpert JR (1995) Escherichia coli expression of site-directed
mutants of cytochrome P450 2B1 from six substrate recognition sites: Substrate
specificity and inhibitor selectivity studies. Chem Res Toxicol 5:574-579.
Hernandez CE, Kumar S, Liu H, and Halpert JR (2006) Investigation of the role of
cytochrome 2B4 active site residues in substrate metabolism based on crystal structures
of the ligand-bound enzyme. Arch Biochem Biopys 455:61-67.
Imaoka S, Yamada T, Hiroi T, Hayashi K, Sakaki T, Yabusaki Y, and Funae Y (1996)
Multiple forms of human P450 expressed in Saccharomyces cerevisiae: systematic
characterization and comparison with those of the rat. Biochem Pharmacol 5:1041-1050.
Kedzie KM, Balfour CA, Escobar GY, Grimm SW, He Y, Pepperl DJ, Regan JW,
Stevens JC, and Halpert JR (1991) Molecular basis for a functionally unique
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
27
cytochrome P450 2B1 variant. J Biol Chem 266:22515–22521.
Kent UM, Hanna IH, Szklarz GD, Vaz ADN, Halpert JR, Bend JR, and Hollenberg
PF (1997) Significance of glycine 478 in the metabolism of N-benzyl-1-
aminobenzotriazole to reactive intermediates by cytochrome P450 2B1. Biochemistry
36:11707–11717.
Kent UM, Jushchyshyn MI, and Hollenberg PF (2001) Mechanisn-based inactivators
as probes of cytochrome P450 structure and function. Curr Drug Metab 2:215–243.
Kent UM, Lin HL, Noon KR, Harris, DL, and Hollenberg PF (2006) Metabolism of
bergamottin by cytochromes P450 2B6 and 3A5. J Pharmacol Exp Ther 318:992-1005.
Lin HL, Zhang H, Waskell L, and Hollenberg PF (2003) Threonine-205 in the F helix
contributes to androgen 16β-hydroxylation activity and mechanism-based inactivation. J
Pharmacol Exp Ther 306:744-751.
Lin HL, Kent UM, Zhang H, Waskell L, and Hollenberg PF (2004) The functional role of
threonine-205 in the mechanism-based inactivation of P450 2B1 by two ethynyl
substrates: the importance of the F helix. J Pharmacol Exp Ther 311:855-863.
Lin HL, Kent UM, and Hollenberg PF (2005) The grapefruit juice effect is not limited to
cytochrome P450 (P450) 3A4: Evidence for bergamottin-dependent inactivation, heme
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
28
destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp
Ther 313:154-164.
Lin HL, Zhang H, Pratt-Hyatt MJ, and Hollenberg PF (2011) Thr302 is the site for the
covalent modification of human cytochrome P450 2B6 leading to mechanism-based
inactivation by tert-butylphenylacetylene. Drug Metab Dispos 39:2431-2439.
Paine MF, Criss AB, and Watkins PB (2004) Two major grapefruit juice components
differ in intestinal CYP3A4 inhibition kinetics and binding properties. Drug Metab
Dispos 32:1146-1153.
Rea V, Kolkman AJ, Vottero E, Stronks EJ, Ampt KAM, Honing M, Vermeulen NPE,
Wijmenga SS, and Commandeur JNM (2012) Active site substitution A82W improves
the regioselectivity of steroid hydroxylation by cytochrome P450 BM3 mutants as
rationalized by spin relaxation nuclear magnetic resonance stidies. Biochemistry 51:750-
760.
Shah MB, Pascual J, Zhang Q, Stout CD, and Halpert JR (2011) Structures of
cytochrome P450 2B6 bound to 4-benzylpyridine and 4-(4-nitrobenzyl)pyridine: insight
into inhibitor binding and rearrangement of active site side chains. Mol Pharmacol
80:1047-1055.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
29
Shah MB, Wilderman PR, Pascual J, Zhang Q, Stout CD, and Halpert JR (2012)
Conformational adaptation of human cytochrome P450 2B6 and rabbit cytochrome P450
2B4 revealed upon binding multiple amlodipine molecules. Biochemistry 51:7225-7238.
Spatzenegger M, Liu H, Wang Q, Debarber A, Koop DR, and Halpert JR (2003) Analysis
of differential substrate selectivities of CYP2B6 and 2E1 by site-directed mutagenesis
and molecular modeling. J Pharmacol Exp Ther 304:477-487.
Stevens JC, White RB, Hsu SH, and Martinet M (1997) Human liver CYP2B6-catalyzed
hydroxylation of RP 73401. J Pharmacol Exp Ther 282:1389-1395.
Szklarz GD, He YA, and Halpert JR (1995) Site-directed mutagenesis as a tool for
molecular modeling of cytochrome P450 2B1. Biochemistry 34:14312–14322.
Szklarz GD, He YQ, Kedzie KM, Halpert JR and Burnett VL (1996) Elucidation of
amino acid residues critical for unique acivities of rabbit cytochrome P4502B5 using
hybrid enzymes and reciprocal site-directed mutagenesis with rabbit cytochrome
P450 2B4. Arch Biochem Biophys 327:308-318.
Turpeinen M, Raunio H, and Pelkonen O (2006) The functional role of CYP2B6 in
human drug metabolism: substrates and inhibitors In Vitro, In Vivo and In Silico. Curr
Drug Metab 7:705-714.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
30
Wang H and Tompkins LM (2008) CYP2B6: new insights into a historically overlooked
cytochrome P450 isozyme. Curr Drug Metab 9:598-610.
Wang Q and Halpert JR (2002) Combined three-dimensional quantitative
structureactivity relationship analysis of cytochrome P450 2B6 substrates and protein
homology modeling. Drug Metab Dispos 30:86–95.
Waxman DJ, Ko A, and Walsh C (1983) Regioselectivity and stereoselectivity of
androgen hydroxylations catalyzed by cytochrome P450 isozymes purified from
phenobarbital-induced rat liver. J Biol Chem 258:11937–11947.
Williams PA, Cosme J, Sridhar V, Johnson EF, and McRee DE (2000) Mammalian
microsomal cytochrome P450 monooxygenase: structural adaptations for
membrane
binding and functional diversity. Mol Cell 5:121–131
Wood AW, Ryan DE, Thomas PE, and Levin W (1983) Regio- and stereoselective
metabolism of two C19 steroids by five highly purified and reconstituted rat hepatic
cytochrome P450 isozymes. J Biol Chem 258:8839–8847.
Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, and Schwab M (2007)
Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance.
Pharmacogenomics 8:743-757.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
31
Zhang H, Lin HL, Walker VJ, Hamdane D, and Hollenberg PF (2009) tert-
Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4:
inhibition of cytochrome P450 catalysis by steric hindrance. Mol Pharmacol 76:1011-
1018.
Zhang H, Lin HL, Kenaan C, and Hollenberg PF (2009) Tatgeting of the highly
conserved threonine 302 residue of cytochromes P450 2B family during mechanism-
based inactivation by aryl acetylenes. Arch Biochem Biophys 507: 135-143.
Zhao Y and Halpert JR (2007) Structure-function analysis of cytochromes P450 2B.
Biochim Biophys Acta 1770:402-412.
Zhao Y, Sun L, Muralidhara BK, Kumar S, White MA, Stout CD, and Halpert JR (2007)
Structural and thermodynamic consequences of 1-(4-chlorophenyl)imidazole binding to
cytochrome P450 2B4. Biochemistry 46:11559-11567.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
32
Footnotes
This work was supported in part by a National Institutes of Health Grant [CA-16954] to
PFH.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
33
Legends for Figures
Fig. 1. Locations of mutated residues in the CYP2B6 crystal structure and the chemical
structures of substrates utilized in the study. A, the locations of Phe206, Thr302, and
Val367 in the CYP2B6 crystal structure are shown (PDB 3IBD). The ribbon model
shows the spatial relationships between the heme (red) and these three residues. The
SRS-2 (magenta), SRS-4 (green) and SRS-5 (blue) residues are colored as indicated. B,
structures of BPA, BG, EFC, Testo and Andro. The carbon atoms of the geranyl side
chain of BG are numbered and the sites of oxidation of BPA and BG to form the reactive
intermediates are circled.
Fig. 2. Metabolism of Testo by the WT and mutant P450s. A, HPLC chromatograms of
the metabolites. CYP2B6 samples of WT, F206A, and V367A were incubated with Testo
and NADPH in the reconstituted system at 37°C for 15 min. The reaction mixtures were
extracted with ethyl acetate in the presence of 6β-OH-Testo (internal standard) and
analyzed by HPLC as described under Materials and Methods. B, Relative amounts of
the metabolites formed by the three CYPs. The formation of 16β-OH-Testo by the WT
was used as 100% to calculate the relative activities for the metabolites produced by WT,
F206A and V367A. The results shown represent the average from two separate
experiments.
Fig. 3. Metabolism of Andro by the WT and mutant CYPs. A, HPLC chromatograms of
the metabolites. The CYPs were incubated with Andro and NADPH in the reconstituted
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
34
system at 37°C for 15 min. The reaction mixtures were extracted with ethyl acetate in the
presence of 16β-OH-Testo (internal standard) and analyzed by HPLC as described under
Materials and Methods. B, Relative amounts of the metabolites formed by the three
CYPs. The formation of 16β-OH-Andro by the WT was used as 100% to calculate the
relative activities for the metabolites produced by WT, F206A and V367A. The results
shown are the mean from two separate experiments.
Fig. 4. Relative amounts of 16α- and 16β-hydroxylation products of Testo (A) or Andro
(B) formed by the WT, F206A and V367A mutants of CYP2B6. The relative amounts of
the 16α-OH metabolite and the 16β-OH metabolite of Testo or Andro formed by each
CYP were calculated using the total amounts of the 16α-OH and 16β-OH metabolites as
100%. The data are taken from Fig. 2 for Testo and Fig. 3 for Andro.
Fig. 5. Loss of EFC deethylation activity of the WT and mutants after the reconstituted
reaction mixtures were incubated with NADPH in the absence (Control) or presence of
10 μM BPA or 10 μM BG for the indicated times. The EFC deethylation activity at time
zero for each condition was used as 100%. Linear regression analysis of the data (Ln %
activity remaining as a function of incubation time) was used to determine the rate
constant of inactivation (kobs). The results presented here are the average of two separate
experiments done in triplicate.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
35
Fig. 6. Determination of the IC50 values for BG inhibition of 100 μM EFC deethylation
activity by 2 μM of the WT (�) and F206A mutant (�). BG concentrations from 0 to 4
μM were used for the inhibition. The activity of each CYP in the absence of BG was used
as 100% control. The activity measured versus the log [BG (nM)] was fitted to the dose
response-inhibition equation using Prism software.
Fig. 7. Determination of the Ki values for inhibition of EFC deethylation activity of WT
2B6 by BG. A, A nonlinear regression plots of the data. The concentrations of EFC
ranged from 1 to 100 μM, as shown. The concentrations of BG were 0 (�), 0.2 μM (�),
0.3 μM (�), 0.5 μM (�), and 1 μM (�). The data presented were fitted to the Michaelis-
Menten equation as described in Materials and Methods. The kinetic parameters for WT
are shown in Table 2 for each concentration of BG. B, Dixon plots of the data in A. 1/V
versus BG concentration shows the inhibition of EFC deethylation activity by BG. The
concentrations of EFC were 1 (�), 2.5 μM (�), 10 μM (�), 25 μM (�), 50 μM (�),
and 100 μM (�). The apparent Ki was estimated from the intersection of the lines from
data obtained at various BG concentrations (Paine et al., 2004).
Fig. 8. Determination of the Ki values for inhibition of EFC deethylation activity of the
F206A mutant by BG. The concentrations of EFC ranged from 1 to 100 μM as indicated
in the Figure. The concentrations of BG were 0 (�), 0.003 μM (�), 0.005μM (�), 0.01
μM (�), and 0.02 μM (�). The data presented were fitted to the Michaelis-Menten
equation as described in Materials and Methods. The kinetic parameters are shown in
Table 2 for each concentration of BG. B, Dixon plot of data in A. 1/V versus BG
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
36
concentration shows the inhibition of EFC deethylation activity by BG. The
concentrations of EFC were 1 (�), 2.5 μM (�), 10 μM (�), 25 μM (�), 50 μM (�),
and 100 μM (�). The apparent Ki was estimated from the intersection of the lines from
data obtained at various BG concentrations (Paine et al., 2004).
Fig. 9. Metabolism of BG by WT 2B6 and the F206A mutant. The P450 reconstituted
systems were incubated with BG at 37°C for 15 min and the reaction mixtures were
extracted with ethyl acetate. The metabolites of BG were analyzed by HPLC as described
in Materials and Methods. The internal standard, 5-methoxypsoralen, eluted at 15 min.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
37
Table 1. Kinetic constants for P450 inactivation by BPA and BGa
Inactivator P450 KI kinact kinact/KI
μM min-1 min-1mM-1
BPA WT 2.7 0.20 74
F206A 141 0.28 2
V367A 44 0.26 6
BG
WT
11.6
0.15
13
F206A 2.2 0.13 59
V367A 5.7 0.10 18
aThe catalytic activities of WT, F206A, and V367A were assessed using the EFC
deethylation activity assay and the kinetic values were determined as described in
Materials and Methods. The data shown represent the mean values of two independent
experiments performed in triplicate.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
38
Table 2. Kinetic constants for BG inhibition of EFC deethylation activity catalyzed by
WT and the F206A mutanta
P450 BG (μM) Kmb
(μM)
kobsb
(min-1)
Kic
(μM)
WT
0
1.7
0.80
0.12
0.2 4.2 0.60
0.3 5.0 0.54
0.5 14 0.50
1 20 0.41
F206A
0
3.6
0.56
0.004
0.003 4.6 0.50
0.005 4.9 0.44
0.01 7.3 0.39
0.02 13 0.34
aThe catalytic activities were determined using EFC concentrations from 1 μM to 100
μΜ with different BG concentrations as described under Materials and Methods.
bThe data from Fig. 7A (WT) and Fig. 8A (F206A) were fitted to the Michaelis-Menten
equation using Prism software (GraphPad software Inc., San Diego, CA).
cThe data were obtained by global fitting to a mixed model inhibition equation using
Prism software. The values are the mean of two separate experiments run in triplicate.
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
DMD # 71662
39
Table 3. Comparison of Testo and Andro metabolism by CYP2B6 to the results
previously published results for CYP2B1 and CYP2B4a.
P450
Testo
Andro
2B1
WT
16β:16α
1.0
Total (%)b
100
16β:16α
8.0
Total (%)b
100
F206A mutant 0.2 73 0.8 22
V367A mutant 1.6 12 24 62
2B4 WT 0.1 100 6.0 100
F206A mutant ND ND ND ND
V367A mutant 1.7 98 10.3 340
2B6 WT 5.3 100 16.6 100
F206A mutant 0.1 15 0.1 34
V367A mutant 1.2 108 12.6 320
aThe data for CYP2B6 were calculated from Fig. 2 and Fig. 3. The data for CYP2B1 (He
et al., 1994; He et al., 1995) and CYP2B4 (Szklarz et al., 1996; Hernandz et al., 2006)
were previously published.
bThe catalytic activity of the WT was designated as 100% for each of the P450s.
ND: not determined
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
Phe206
Val367
Thr302
Fig 1
tert-butylphenylacetylene (BPA) bergamottin (BG)
testosterone (Testo) androstenedione (Andro)
7-ethoxy-4-(trifluoromethyl)coumarin (EFC)
A B
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
0.000
0.015
0.030
8.00 12.00 16.00 20.00 24.00
WT F206A V367A
16a-OH-Testo
16b-OH-Testo
Andro
Testo
0.000
0.015
0.030
8.00 12.00 16.00 20.00 24.00
0.000
0.015
0.030
8.00 12.00 16.00 20.00 24.00
Internal standard: 6b-OH-Testo
Time (min)
8 12 16 20 24
Rel
ativ
e ab
sorb
ance
at
25
4 n
m 16b-OH-Testo in WT
as 100% control
Re
lati
ve c
atal
ytic
act
ivit
y
(% o
f co
ntr
ol)
A
WT
F206A
V36
7A
0
25
50
75
100
16a-OH-Testo
16b-OH-Testo
Andro
Fig 2
16a-OH-Testo
16a-OH-Testo
16b-OH-Testo
Andro
Andro
B
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
0.00
0.09
0.18
8.00 12.00 16.00 20.00 24.00
0.00
0.09
0.18
8.00 12.00 16.00 20.00 24.00
0.00
0.09
0.18
8.00 12.00 16.00 20.00 24.00
16b-OH-Andro
WT
F206A
V367A
Andro
16a-OH-Andro
Internal standard:
16b-OH-Testo
16a-OH-Andro
16b-OH-Andro
8 12 16
Time (min)
Rela
tive a
bsorb
ance a
t 254 n
m
WT
F206A
V36
7A
0
50
100
150
200
250
300
16b-OH-Andro
16a-OH-Andro
16b-OH-Andro in WT
as 100% control
Re
lati
ve
ca
taly
tic
ac
tivit
y
(%
of
co
ntr
ol)
A
Fig 3
B
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
Testo
Andro
% o
f to
tal a
ctiv
ity
%
of
tota
l act
ivit
y
WT
F206A
V367A
0
20
40
60
80
10016
16
WT
F206A
V367A
0
20
40
60
80
10016
16
Fig 4
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
0 3 6 9
1
2
3
4
5
W T
T i m e ( m i n )
0 3 6 9
1
2
3
4
5
V 3 6 7 A
T i m e ( m i n )
n o i n h i b i t o r
B P A
B G
0 3 6 9
0
1
2
3
4
5
F 2 0 6 A
T i m e ( m i n )
Ln %
Act
ivit
y re
mai
nin
g
BPA: 0.16 min-1
BG: 0.15 min-1 BPA: 0.04 min-1
BG: 0.13 min-1 BPA: 0.04 min-1
BG: 0.10 min-1
Fig 5
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
Log [BG (nM)]
0 1 2 3 40
20
40
60
80
100
EFC
de
eth
ylat
ion
act
ivit
y
(
% o
f co
ntr
ol )
Fig 6
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
EFC (M)
0 20 40 60 80 1000.0
0.2
0.4
0.6
0.80
0.2 mM BG
0.3 mM BG
0.5 mM BG
1.0 mM BG
BG (M)
-0.5 0.5 1.0
-5
5
10
15
20 1 EFC
2.5
10
25
50
100
Fig 7
1/k
ob
s (m
in-1
)
k ob
s (m
in-1
)
A B
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
EFC (M)
0 20 40 60 80 1000.0
0.2
0.4
0.60 BG
0.003
0.005
0.01
0.02
BG (M)
-0.01 0.01 0.02
-10
-5
5
10
15
20
251 EFC
2.5
10
25
50
100
A B
k ob
s (m
in-1
)
1/k
ob
s (m
in-1
)
Fig 8
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from
0.000
0.025
0.050
15.00 30.00 45.00 60.00
0.000
0.025
0.050
15.00 30.00 45.00 60.00
0.000
0.025
0.050
15.00 30.00 45.00 60.00
Internal standard
M3
M3
M4
M4
Re
lati
ve a
bso
rban
ce (
31
0 n
m)
15 30 45 60
Time (min)
BG
BG
BG
WT F206A V367A
Fig 9
This article has not been copyedited and formatted. The final version may differ from this version.DMD Fast Forward. Published on August 18, 2016 as DOI: 10.1124/dmd.116.071662
at ASPE
T Journals on M
arch 20, 2021dm
d.aspetjournals.orgD
ownloaded from